Literature DB >> 19826354

Response rates: a valuable signal of promising activity?

Xavier Pivot1, Antoine Thierry-Vuillemin, Cristian Villanueva, Fernando Bazan.   

Abstract

A main criterion to identify activity in phase II studies is the response rates achieved in a well-defined subset of patients. The response could be defined as a measure of tumor shrinkage. For 30 years, metric methods have been used to assess this response. The World Health Organization was the first organization to propose a unified definition for response status. Over time, the latter evolved and 10 years ago an international consensus panel proposed the Response Evaluation Criteria in Solid Tumors criteria. Although these guidelines for response assessment have limitations and biases, they have nevertheless been proven useful and advantageous. This article reviews those criteria and describes their use.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19826354     DOI: 10.1097/PPO.0b013e3181bd045f

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  3 in total

1.  Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials.

Authors:  Ming-Wen An; Sumithra J Mandrekar; Megan E Branda; Shauna L Hillman; Alex A Adjei; Henry C Pitot; Richard M Goldberg; Daniel J Sargent
Journal:  Clin Cancer Res       Date:  2011-08-31       Impact factor: 12.531

2.  Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse.

Authors:  Sumithra J Mandrekar; Ming-Wen An; Jeffrey Meyers; Axel Grothey; Jan Bogaerts; Daniel J Sargent
Journal:  J Clin Oncol       Date:  2014-02-10       Impact factor: 44.544

3.  Can we establish a hierarchy among trastuzumab biosimilar candidates?

Authors:  Xavier Pivot; Thierry Petit
Journal:  Br J Cancer       Date:  2018-07-13       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.